Pluri (NASDAQ:PLUR) Issues Earnings Results

Pluri (NASDAQ:PLUR) released its quarterly earnings results on Thursday. The company reported ($0.71) earnings per share (EPS) for the quarter, Zacks reports.

Pluri Price Performance

PLUR opened at $3.55 on Friday. The stock has a market capitalization of $35.43 million, a PE ratio of -0.75 and a beta of 0.67. The firm’s fifty day moving average price is $3.25 and its 200 day moving average price is $4.02. Pluri has a 12-month low of $2.82 and a 12-month high of $7.13.

Institutional Investors Weigh In On Pluri

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned about 0.14% of Pluri as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 16.59% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pluri in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Pluri presently has a consensus rating of “Hold” and an average price target of $12.00.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.